NO20084857L - HPV-16-basert papillomavirus vaksine - Google Patents

HPV-16-basert papillomavirus vaksine

Info

Publication number
NO20084857L
NO20084857L NO20084857A NO20084857A NO20084857L NO 20084857 L NO20084857 L NO 20084857L NO 20084857 A NO20084857 A NO 20084857A NO 20084857 A NO20084857 A NO 20084857A NO 20084857 L NO20084857 L NO 20084857L
Authority
NO
Norway
Prior art keywords
hpv
preventing
treating
papillomavirus vaccine
papillomavirus
Prior art date
Application number
NO20084857A
Other languages
English (en)
Norwegian (no)
Inventor
Ronald Rooke
Stephane Paul
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of NO20084857L publication Critical patent/NO20084857L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20084857A 2006-04-21 2008-11-18 HPV-16-basert papillomavirus vaksine NO20084857L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360014 2006-04-21
PCT/EP2007/003368 WO2007121895A2 (fr) 2006-04-21 2007-04-17 Vaccin contre le papillomavirus

Publications (1)

Publication Number Publication Date
NO20084857L true NO20084857L (no) 2008-11-18

Family

ID=38362856

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084857A NO20084857L (no) 2006-04-21 2008-11-18 HPV-16-basert papillomavirus vaksine

Country Status (13)

Country Link
US (1) US20100061957A1 (fr)
EP (1) EP2013230A2 (fr)
JP (1) JP2009534332A (fr)
KR (1) KR20090005011A (fr)
CN (1) CN101426811A (fr)
AU (1) AU2007241406A1 (fr)
BR (1) BRPI0710238A2 (fr)
CA (1) CA2649392A1 (fr)
IL (1) IL193661A0 (fr)
MX (1) MX2008013488A (fr)
NO (1) NO20084857L (fr)
RU (1) RU2008145712A (fr)
WO (1) WO2007121895A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8926961B2 (en) * 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CA2721366C (fr) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation de reponse immunitaire par des enantiomeres de lipides cationiques
EP2239330A1 (fr) 2009-04-07 2010-10-13 Institut Pasteur Génération, régénération et protection de neurones
CN103119168A (zh) * 2010-07-15 2013-05-22 不列颠哥伦比亚癌症局分支机构 人乳头瘤病毒e7抗原组合物及其用途
CN102343103B (zh) * 2011-07-26 2016-04-27 马丁 人乳头状瘤病毒16型三肽疫苗的筛选和验证及持续表达hpv16 e5, e6, e7的肿瘤动物模型的构建
EP2601968A1 (fr) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum Acides polynucléiques dérivés du VPH pour thérapie
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
US9000736B2 (en) 2013-05-03 2015-04-07 Cooper Technologies Company Power factor correction algorithm for arbitrary input waveform
US9190901B2 (en) 2013-05-03 2015-11-17 Cooper Technologies Company Bridgeless boost power factor correction circuit for constant current input
US9548794B2 (en) 2013-05-03 2017-01-17 Cooper Technologies Company Power factor correction for constant current input with power line communication
US9214855B2 (en) 2013-05-03 2015-12-15 Cooper Technologies Company Active power factor correction circuit for a constant current power converter
EP3374496A4 (fr) 2015-11-13 2019-07-10 PDS Biotechnology Corporation Lipides en tant que vecteurs synthétiques pour améliorer le traitement et la présentation de l'antigène ex-vivo en thérapie cellulaire dendritique
AU2017272356A1 (en) * 2016-06-03 2018-12-20 Etubics Corporation Compositions and methods for the treatment of human papillomavirus (HPV)-associated diseases
MX2019003961A (es) 2016-10-05 2019-08-26 Pds Biotechnology Corp Vacunas novedosas del vph16 con celulas t no restringidas por hla, composiciones y metodos de uso de las mismas.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
EP1425039A4 (fr) * 2001-03-23 2005-02-02 Us Gov Health & Human Serv Peptides immunoreactifs du papillomavirus humain
DE60332377D1 (de) * 2002-10-21 2010-06-10 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden

Also Published As

Publication number Publication date
JP2009534332A (ja) 2009-09-24
RU2008145712A (ru) 2010-05-27
WO2007121895A2 (fr) 2007-11-01
MX2008013488A (es) 2008-10-30
CA2649392A1 (fr) 2007-11-01
BRPI0710238A2 (pt) 2011-08-09
IL193661A0 (en) 2011-08-01
AU2007241406A1 (en) 2007-11-01
US20100061957A1 (en) 2010-03-11
KR20090005011A (ko) 2009-01-12
WO2007121895A3 (fr) 2008-03-20
EP2013230A2 (fr) 2009-01-14
CN101426811A (zh) 2009-05-06

Similar Documents

Publication Publication Date Title
NO20084857L (no) HPV-16-basert papillomavirus vaksine
WO2007121894A3 (fr) Vaccin contre le papillomavirus à base de hpv-18
MY150855A (en) Oral compositions containing extracts of zizyphus joazeiro and related methods
NO20092360L (no) Nye antiproliferasjonsantistoffer
EP2336174B8 (fr) Anticorps monoclonaux humains contre les virus Hendra et Nipah
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
MX2009011865A (es) Tratamiento de lesiones viralmente inducidas.
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
BR112016029713A8 (pt) uso de uma carboximetilcelulose reticulada e uso de um agente gelificante
MX337932B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
DE602006010564D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
ECSP055869A (es) Vacuna hpv-16 y -18 l1 vlp
MY150604A (en) 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities
BR112018011310A2 (pt) mutante da proteína l1 do papilomavírus humano tipo 58
NO20081014L (no) Sammensetninger
EA201000329A1 (ru) Циклические депсипептиды
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
BR112018011331A2 (pt) mutante de proteìna l1 de papillomavirus humano tipo 11
DE60330257D1 (de) Zusammensetzung zur impfung
ATE498022T1 (de) Universelle vervielfältigung von fragmentierter rns
IN2011KN05169A (fr)
NO20070980L (no) Selekterte kondenserte heterocykler og anvendelser derav
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application